Navigation Links
Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million
Date:10/13/2011

CRANBURY, N.J., Oct. 13, 2011 /PRNewswire/ -- Oncobiologics announced today that it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early-stage biotech company, and involves worldwide licensing for an undisclosed biotherapeutic product. The second is with a US based large pharmaceutical company to conduct research focused on solving issues related to downstream processing of monoclonal antibodies. The identity of the client firm was not disclosed due to confidentiality terms in the agreement. The combined value of the agreements to Oncobiologics totals close to $80 million.

Dennis O'Donnell, CEO of Parilis Biopharmaceuticals said, "We are very excited about this agreement with Oncobiologics.  This is a major step for Parilis in selecting a biotherapeutic candidate with very high potential. Oncobiologics' capabilities will enhance our speed to market and provide a much greater chance for success. Oncobiologics gives us access to a team of senior scientists with decades of large pharma experience. We have every confidence that they have the knowledge and scientific rigor needed to help ensure our mutual success."

Oncobiologics Vice President of Business Development, Jeremy Caudill commented, "These programs represent a significant milestone for Oncobiologics. They are a validation of our dual strategies; as a fully integrated Biopharmaceutical company, as well as providing world-class proof-of-concept services to customers and partners."

Caudill added, "These agreements also recognize the strength and depth of the team assembled here at Oncobiologics. For a major pharmaceutical organization to entrust an important technical program of this scope reflects the confidence they have in our capabilities.  Likewise, Dennis O'Donnell brings a track-record of successes and has chosen Oncobiologics largely on the strength of our team."

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is utilizing a proprietary platform to develop a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Oncobiologics provides world-class, turnkey proof-of-concept services that can take a partner's pre-clinical candidates from chemistry, manufacture and control development all the way through Phase II clinical trials. For more information, please visit www.oncobiologics.com or call 609-619-3990.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform
2. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
3. ULURU Inc. Announces Altrazeal® Agreement for the European Market
4. Mylan Announces Intention to Refinance Existing Secured Credit Facility
5. Health Industry Group Purchasing Association Announces Name Change to Healthcare Supply Chain Association (HSCA) to Reflect Expertise, Experience and Position Within Healthcare Supply Chain
6. I-Flow LLC, a Kimberly-Clark Health Care Company Announces Agreement for ON-Q® Products With HealthTrust Purchasing Group
7. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the Third Quarter Ended September 30, 2011
8. Webcast Alert: Heska Announces Third Quarter 2011 Earnings Conference Call Webcast
9. Lilly Announces Changes in Senior Management
10. Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier
11. Soligenix Announces Formation of Pediatric Crohns Disease Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
Breaking Medicine Technology:
(Date:8/16/2017)... Linda, Ca (PRWEB) , ... August 16, 2017 , ... ... innovators, engineers, and scientists from around the world, is excited to announce Andrew Ly ... him in his academic pursuits, covering textbook costs. , Ly, who is in ...
(Date:8/16/2017)... ... 16, 2017 , ... With a new PD diagnosis every nine minutes, research ... The grants are awarded through a competitive application process and reviewed by APDA’s Scientific ... and expertise in all areas relevant to PD research. The SAB meets annually ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable city ... (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities and ... Melbourne has consistently come in the top three of the index. So what is ...
(Date:8/16/2017)... Fla. (PRWEB) , ... August 16, 2017 , ... ... and management company based in Vero Beach, announced today that two of their ... an organization that represents professionally managed senior living communities in Florida. The awards ...
(Date:8/16/2017)... City, Utah (PRWEB) , ... August 16, 2017 , ... ... on the Inc 5000 list for the fourth consecutive year. With 197% ... 5000 2017 list of the nation’s fastest growing companies. , Previous honors ...
Breaking Medicine News(10 mins):